Analysts Set Expectations for XBIO FY2026 Earnings

Xenetic Biosciences Inc (NASDAQ:XBIO) – Equities research analysts at HC Wainwright issued their FY2026 EPS estimates for Xenetic Biosciences in a report released on Monday, November 11th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.64) per share for the year. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Xenetic Biosciences’ current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Xenetic Biosciences’ FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.75) EPS.

Xenetic Biosciences Stock Performance

Shares of XBIO stock opened at $3.69 on Thursday. The stock’s 50-day moving average is $3.89 and its two-hundred day moving average is $3.93. Xenetic Biosciences has a 1 year low of $2.78 and a 1 year high of $5.20. The firm has a market cap of $5.68 million, a price-to-earnings ratio of -1.39 and a beta of 2.25.

Xenetic Biosciences (NASDAQ:XBIO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.14). Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. The company had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.75 million.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.